THEME: "Frontiers in Biotechnology and Bioengineering Research"
LifeSci Capital LLC, United States.
Title: The Five Reasons Biotech Companies Fail to Raise Capital and How to Fix Them
David is an experienced healthcare capital markets
investment banker with a career focused on helping high-growth life science,
medical device, and healthcare IT companies achieve their financial and
strategic goals. Prior to joining LifeSci Capital, David founded Dobkin &
Company, an investment bank tailored for entrepreneur-lead companies focused on
seed and growth equity and capital. Previously, David worked in various
capacities with the New Zealand Government facilitating capital formation on
behalf of regional companies and government agencies with a focus on securing
strategic foreign direct investment. David has tremendous experience conducting
cross-border transactions. Prior to October 2010, David worked for Lazard
Frères, one of the world’s preeminent financial advisory and asset management
firms, where he facilitated and advised on cross-border mergers and
acquisitions transactions in excess of $3 billion. Prior to joining for Lazard
Frères, David began his career in the Healthcare investment banking group for
Wasserstein Perella based in New York. David conducted graduate research in
stem cell bio-engineering and received a Master of Science, Biomedical
Engineering, from the University of Southern California. David also received a
Bachelor of Science, Biomedical Engineering, from Columbia University.